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Purpose: The purpose of this study was to determine the effects of down-regulation of Aquaporin 1 (AQP1) and Aquaporin
5 (AQP5) on cell proliferation and migration in human corneal endothelial (HCEC) and human corneal epithelial (CEPI17)
cell lines, respectively.
Methods: AQP1 and AQP5 were down regulated using siRNA following lipofectamine-mediated transfection in corneal
endothelial  and  epithelial  cells,  respectively.  Down-regulation  was  confirmed  using  RT–PCR,  indirect
immunofluorescence, and immunoblot analysis. Total internal reflection fluorescence (TIRF) microscopy was used to
detect cell surface aquaporin expression. Cell proliferation was determined by SRB (sulfrodamine B) assay. Cell migration
was determined by in vitro wound healing and migration assay.
Results: In HCEC cells, AQP1 was localized to the cytosol as well as cell membrane and its down-regulation resulted in
decreased cell proliferation and migration with a significant decrease in phosphorylated ERK (pERK). In CEPI17 cells
AQP5 protein expression was also localized to cytosol as well as cell membrane. AQP5 down-regulation resulted in an
increase in proliferation and cell migration with no significant difference in pERK.
Conclusions: AQP1 plays a role in HCEC proliferation and migration via the ERK signaling pathway and therefore may
have significant implications in corneal endothelial dysfunction whereas; AQP5 may play an indirect role in human corneal
epithelial cell proliferation and migration.
Aquaporins  (AQP)  are  a  class  of  membrane
glycoproteins,  embedded  in  the  cell  membrane,  which
function mostly as semi-selective pores allowing water to
move in response to osmotic and hydrostatic differences [1].
The  diverse  requirement  for  the  regulation  of  water
homeostasis in different cells and tissues is one of the major
reasons for the numerous aquaporins (AQP0-AQP12) that are
present [2]. The predominant and well studied function of
AQP is the regulation of water transport [3]. Recent studies
have  implicated  other  possible  functions  that  include  cell
migration (angiogenesis, tumor metastasis, wound healing
[4], neural function (sensory signaling, seizures) [5] and even
differentiation [6]. In the area of vision research, aquaporins
have  been  implicated  in  certain  ocular  disorders  such  as
keratoconus [7], bullous keratopathy, and Fuchs' dystrophy
[8], and glaucoma [9].
AQP1  and  AQP5  both  play  an  important  role  in  the
maintenance of corneal hydration Alterations of the amount
and/or location of expression of AQP1 and AQP5 have been
investigated in a variety of pathological conditions [10-13].
AQP1 is the first molecular water channel that was discovered
in red blood cells [14]. In the eye, this protein is expressed in
cells from the lens epithelium, corneal endothelium, stroma,
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trabecular  meshwork,  and  the  ciliary  non-pigmented
epithelium [15]. AQP1 expression levels have been shown to
be  associated  with  changes  in  corneal  hydration  and
maintenance of thickness of the stroma. Changes in corneal
thickness can result in impairment of corneal transparency,
which is crucial for vision [16]. While it is unclear if down
regulation of AQP1 is directly related to corneal endothelial
disease, it is suggested that increased AQP1 expression may
reduce corneal edema [17]. Maintenance of corneal stromal
transparency requires precise regulation of extracellular water
content [18]. AQP5 is predominantly expressed in the corneal
epithelium and the apical membranes of the lacrimal acini
[1]. It is interesting to note that AQP5 is absent in the corneal
endothelium where AQP1 is abundantly expressed. AQP5 has
been shown to be involved in the maintenance of corneal
hydration,  which  is  necessary  to  maintain  corneal
transparency [17].
Cell  proliferation  and  migration  are  two  important
aspects of wound healing. Overexpression and knock down
studies have been extensively used to study the role of AQPs
in normal and diseased tissues. AQP1 has also been shown to
be involved in cell migration in several cell types such as
keratocytes [19], epithelial cells of the kidney [20], and gastric
epithelial  cells  [21].  Recently  it  was  shown  that  AQP1
contributes to cell migration in endothelial and melanoma cell
lines via association with Lin7/β catenin [22]. In addition,
AQP5 has been shown to be involved to some extent in cell
proliferation and carcinogenesis in colon, gastric, and ovarian
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1538cancer tissues [6]. It is however unclear if this is a tissue/cell
type specific occurrence. The role of AQP1 and AQP5 in
corneal wound healing has not been studied. We examined the
role of AQP1 and AQP5 in cell migration and proliferation in
the  human  corneal  endothelial  cell  (HCEC)  and  SV40
immortalized  corneal  epithelial  (CEPI17)  cell  lines,
respectively. We show here that down regulation of AQP1 and
AQP5  using  target  specific  siRNA  has  an  impact  on  cell
proliferation and migration and hence, may have implications
in wound healing in the cornea.
METHODS
All tissue samples were obtained in compliance with good
clinical practice, with informed consent under Institutional
Review Board (IRB) regulations, and also in accordance with
the tenets of the Declaration of Helsinki.
Cell culture:
Primary  human  corneal  epithelial  cells—Epithelial
sheets were obtained from Eye Bank corneas (after removal
of residual sclera and conjunctiva tissue) and the primary cells
cultured as previously described [23]. Briefly, donor tissue
was incubated in dispase (BD Biosciences, San Jose, CA),
diluted  with  calcium  free  EpiLife®  (Cascade  Biologicals,
Portland, OR) medium to 12 Units/ml at 4 °C for 48 h. The
epithelial sheets were removed from the stromas, dissociated
into single cell suspension, and then plated into tissue culture
(TC) flasks (75 cm2, vented). Flasks were coated with murine
collagen type IV (at a concentration of 5 μg/ml) using a cell
scraper to evenly coat the entire growth surface. The coated
flasks were air-dried under sterile conditions before use (or
stored sterile at 4 °C). The cells were cultured in serum free
defined  media  (EpiLife®;  Cascade  Biologicals)  until
approximately  80%  confluent,  and  then  sub  cultured  by
harvesting with trypsin/EDTA (Gibco BRL, Carlsbad, CA),
neutralization of proteolytic activity with trypsin inhibitor
(Sigma-Aldrich,  St  Louis,  MO),  and  plating  into  freshly
collagen IV coated TC flasks (BD Biosciences).
Human corneal epithelial cell line—CEPI17 (SV-40
transformed Corneal epithelial cell line) [24] (a kind gift from
Dr.  Slobodan  Dimitrijevich  Department  of  Integrative
Physiology,  UNTHSC,  Fort  Worth,  TX)  were  cultured  in
serum free defined media (EpiLife®; Cascade Biologicals) to
80% confluence. The epithelial cells were sub cultured by
harvesting with trypsin/EDTA (Gibco BRL), neutralization of
proteolytic activity with trypsin inhibitor (Sigma-Aldrich),
and plating into fresh collagen IV coated TC flasks. These
cells, also referred to as CEPI-17-CL4, have been considered
a suitable corneal epithelial cell model and are currently being
widely used [25].
Corneal  endothelial  cell  line—HCEC  (E6/E7
transformed endothelial cells, a kind gift from Dr. Slobodan
Dimitrijevich,  Department  of  Integrative  Physiology,
UNTHSC, Fort Worth, TX) [26] were cultured in DMEM
supplemented with 10% FBS.
Immunocytochemistry: Approximately 15,000 cells were
plated  on  glass  coverslips  (12  cm2,  Thermofisher;  Fisher
Scientific, Pittsburgh, PA) and cultured in their respective
media. When the cultures had stabilized, the coverslips were
rinsed in PBS, and fixed/permeabilized in methanol: acetone
(1:1,  10  min  at  −20  °C).  After  re-hydration  in  phosphate
buffered  saline  (PBS,  0.256  g/l  NaH2PO4  H2O,  1.19  g/l
Na2HPO4, 8.76 g/l NaCl, pH 7.4; for 30 min), and distilled
water washes (3×) the cells were blocked (overnight at 4 °C)
in PBS + 1% BSA (BSA). The cells were then rinsed with PBS
and distilled water (3×), and incubated at 4 °C, overnight, with
primary (1°) antibody diluted in PBS. After rinsing in PBS
containing Tween-20 (0.1%; 3×10 min), cells were incubated
with secondary (2°) antibody at room temperature (RT, 1.5 h)
and  rinsed  in  PBS  +  Tween-20  (0.1%,  3×10  min).  The
specimens were rinsed in PBS (3×10 min), distilled water (30
min), stained with 4’, 6-diamino-2-phenylindole (DAPI) and
mounted on glass slides (FluorSave; Calbiochem, La Jolla,
CA). Cells on coverslips stained with secondary antibody
alone were used as negative controls, which showed virtually
no fluorescence.
Antibodies:  Anti-AQP5,  anti-AQP1  and  anti-GAPDH
primary  antibodies  were  purchased  from  Santa  Cruz
Biotechnology  (Santa  Cruz,  CA).  Anti-ERK,  anti-
phosphorylated ERK antibodies were purchased from BD
biosciences.  Alexa  Fluor  594  nm  goat  anti-mouse,  Alexa
Fluor 594 goat-anti-rabbit and Alexa Fluor 594 nm donkey
anti-goat  (Molecular  Probes/Invitrogen,  San  Diego,  CA)
secondary  antibodies  were  used  at  dilutions  of  1:1,000.
Negative controls in all experiments were specimens labeled
with 2° antibody only and DAPI to show nuclei; these showed
virtually no background fluorescence.
Image acquisition: Mounted specimens were examined
on Olympus AX70 fluorescent microscope (Olympus, Center
Valley,  PA)  using  SPOT  Twain  software  (Microsoft,
Issaquah, WA).
Transfection: Cells were cultured and transfected using
Lipofectamine  2000  (Molecular  Probes/Invitrogen)  when
they were 70% confluent. Transfection was performed as per
manufacturer’s instructions. CEPI17 and HCEC cells were
transfected with 100 nM concentration of On-TARGET plus
SMART pool AQP5 (Dharmacon, Pittsburgh, PA) and On-
TARGET  plus  SMART  pool  AQP1  (Dharmacon),
respectively. Transfection of cells with 100 nM Non Targeting
siRNA#3 (siGENOME® Control siRNA; Dharmacon) served
as a transfection control. Transfected cells were then used for
further analysis.
RNA isolation and RT–PCR: RNA was isolated using
Trizol®  reagent  according  to  manufacturer’s
recommendations  for  cells  cultured  as  monolayer
(Invitrogen). Trizol (1 ml/cm2 of cell monolayer) was added
to the washed cell monolayer and the cells detached from the
flask using a cell scraper. The cells mixture was transferred to
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scraped. To this 0.2 ml of chloroform was added and the
closed tube shaken vigorously by hand for 15 s, opened and
incubated  at  30  °C  for  2–3  min.  The  sample  was  then
centrifuged at no more than 12,000× g (2–8 °C) for 15 min.
The top aqueous layer was carefully removed and transferred
to a fresh centrifuge tube and the RNA precipitated with
isopropanol (0.5 ml of isopropanol/ml of Trizol reagent used).
The precipitated RNA was washed twice with ethanol and
finally dissolved in DEPC treated water. Primers used were
as follows: AQP5 (forward: 5′-AAG GCC GTG TTC GCA
GAG TT-3′, reverse: 5′-TGG TCA GCT CCA TGG TCT
TC-3′, annealing temperature: 55 °C); AQP1 (forward: 5′-
CTT ACC TCC AGG ACC CTT CC-3′, 
reverse: 5′-TAG CTC ATC CAC ACG TGC TC-3′, annealing
temperature:  60  °C).  RT–PCR  was  performed  using
Superscript®  One  step  RT–PCR  system  (Invitrogen).
Agarose gel (1.2%) was prepared by heating agarose in TAE
buffer. After cooling, ethidium bromide (6 μl in 100 ml of
solution) was added to the mixture. The total sample obtained
from  RT–PCR  was  loaded  on  to  the  gel  with  5  μl  of
bromophenol  blue  dye  and  imaging  was  performed  using
UVP imaging device.
Western blot analysis: Cultured epithelial and endothelial
cells were treated with lysis buffer (2.5 ml 1 M Tris buffer
[pH=7.0], 1 g SDS, and 2.5 g sucrose in 50 ml distilled water)
for 5 min at RT as previously described [26]. Genomic DNA
was sheared by several passes through a 22-gauge needle, and
samples stored at –20 °C until needed. BCA (bicinchoninic
acid) protein assays (Pierce, Rockford, IL) of lysates were
performed to determine the protein concentration (and ensure
equal loading of lanes). SDS PAGE was performed at RT, and
20 μg protein/lane was loaded with 12% Tris-Glycine, at 150
V in Tris/glycine as the running buffer. Protein bands were
transferred  onto  nitrocellulose  membranes  (VWR
International, Irving, TX) by electro-blotting overnight (4 °C)
at 10 V in Tris/glycine buffer with 20% methanol and transfer
was confirmed with Ponceau Red (Sigma-Aldrich) staining of
the  membranes.  After  de-staining  in  distilled  water,
membranes were incubated in blocking buffer (5% powdered
milk and 1% BSA in PBS) for 1 h (RT). Membranes were then
incubated with 1° antibody for 30 min (RT), then overnight
(4 °C) and finally the following morning for 30 min (RT).
After rinsing in PBS containing 0.1% Tween-20 (3×10 min),
the membranes were incubated with 2° antibody for 1 h (RT),
rinsed  in  PBS  with  0.1%  Tween-20  (3×10  min),  and
developed  (ECL  Chemiluminescence;  Amersham
Biosciences,  Little  Chalfont,  UK).  Densitometric  analysis
was performed on the western blot images using Image J
(nih.gov)  to  quantitate  the  amount  of  mRNA  and  protein
levels following transfection with target specific siRNA at
different time points.
TIRF microscopy: Primary human corneal epithelial and
CEPI17  cells  were  grown  on  coverslips  and  mounted  on
24×60  cover  glass  (Falcon#1;  Fisher  Scientic,  Pittsburgh,
PA).  Unpermeabilized  cells  were  immunostained  with
combinations  of  primary  antibodies  and  Alexa-fluor
secondary antibodies (1:1,000; Molecular probes). We also
used a cytosolic protein (tubulin) to eliminate cytosolic epi-
fluorescence. The cells were examined under the Olympus
IX71 microscope (Olympus, Center Valley, PA) equipped
with a commercial TIRF attachment (60×) at the Center for
Commercialization of Fluorescence Technologies (CCFT),
UNTHSC.
In vitro wound healing assay: Cells were seeded at high
density in 6 well plates 72 h after transfection with siRNA.
Two  (or  more)  parallel  scratch  wounds  of  approximately
400 μm width were made perpendicular to the marker lines
with a yellow P200 pipette tip (Fisher). This procedure makes
it possible to image the entire width of the wound using a 4×
objective.  The  wounds  are  observed  using  phase  contrast
microscopy on an inverted microscope. Images were taken at
regular intervals over the course of 0–36 h of both areas
flanking the intersections of the wound and the marker lines
(5  images  per  experimental  condition).  The  width  of  the
wound was controlled so that it is as consistent as possible,
since narrow wounds tend to close faster than wider wounds.
If more than two scratches were made, wounds with similar
widths were chosen for analysis. Images were analyzed by
digitally drawing lines (using Image J software) averaging the
position of the migrating cells at the wound edges. The cell
migration distance was determined by measuring the area of
the  wound  under  different  experimental  conditions  and
compared to the control.
In vitro invasion assay: HCEC cells both control and
those transfected with AQP1 siRNA were treated with Cell
Tracker Green® for 2 h (Invitrogen, Carlsbad, CA). The cells
were then seeded onto Matrigel endothelial cell migration
chambers  (BD  Biosciences,  San  Jose,  CA)  72  h  after
transfection. These chambers were hydrated for at least 2 h in
the tissue culture incubator with 500 μl serum free DMEM in
the bottom of the well and 500 μl in the top of the chamber.
After hydration of the Matrigel, the DMEM in the bottom of
the well was replaced with DMEM containing 10% FBS.
HCEC  cells  (500,000)  were  plated  in  500  μl  of  DMEM
supplemented with 10% FBS in the top of the chamber. The
invasion assay was performed for 24 h in the tissue culture
incubator.  The  cells  were  fixed  by  replacing  the  culture
medium  in  the  bottom  and  top  of  the  chamber  with  4%
formaldehyde dissolved in PBS. The cells that migrated were
counted using an inverted microscope equipped with either a
4× or a 10× objective and plotted as the percentage of invading
cells of the total number of plated cells.
Sulfrodamine B (SRB) cell proliferation assay: The SRB
proliferation assay was performed as described earlier [27].
Briefly, control and transfected cells (CEPI 17 and HCEC)
were seeded in a 96 well plate at a cell density of 5,000 cells/
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1540well 24, 48, and 96 h after transfection. On days 2, 3, and 5,
the media was removed and cells were fixed with 10% TCA
for 10 min at 4 °C. The cells were washed 4 times with distilled
water, and then stained 10 min with SRB dissolved in 1.0%
acetic acid. The plates were washed 4 times with 1.0% acetic
acid and allowed to air dry. At this point they were stable and
left overnight or longer at room temperature. Prior to reading
the plates, 200 µl of 10 mM Tris base (unbuffered) was added
per well to solublize the dye. The plates were mixed for 5 min
on  a  Lab  Line  Instruments  Titer  Plate  Shaker  (VWR
International, Irving, TX) and read at 564nm on a Molecular
Devices  SpectraMax  340  (Molecular  Devices,  Sunnyvale,
CA), using Soft Pro Max acquisition software (Molecular
Devices). Absorbance data were exported into a Microsoft
Excel  spreadsheet  (Microsoft)  for  further  analysis.  Cell
densities were obtained by correcting absorbances for media
controls and used for statistical analysis.
Statistical analysis: Statistical analysis was performed
using paired Student’s t-test and a p-value <0.05 was taken as
statistically significant for all the experiments.
RESULTS
Sub-cellular  localization  of  AQP1  in  HCEC  cells:  The
localization  of  AQP1  was  investigated  by
immunocytochemistry  using  mouse  AQP1  monoclonal
antibody  in  HCEC  cells.  HCEC  cells  stained  with  only
fluorescent secondary antibody served as negative controls.
As shown in Figure 1A, AQP1 was detected in the cytosol as
well as membrane-associated regions of the HCEC cells as
observed  by  fluorescence  microscopic  analysis.  Negative
controls showed virtually no fluorescence (data not shown).
Sub-cellular  localization  of  AQP5  in  CEPI17  cells:  The
cellular and sub cellular localization of the AQP5 protein in
CEPI17  cells  was  investigated  by  immunocytochemistry,
using rabbit polyclonal anti-AQP5 antibody. As seen in Figure
Figure 1. Immunocytochemical localization analysis of AQP expression in corneal cell lines. The panels show (A) AQP1 expression (red) in
HCEC cells, (B) Z-sectioning analysis showing AQP5 expression (green) in CEPI17 cells, and (C) Z-sectioning analysis showing AQP5
expression (green) in Primary WT CEPI cells. TIRF microscopic analysis showing the membrane association of AQP5 in CEPI17 cells is
seen in panel D.
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15411B, AQP5 is localized to both cytosol as well cell membrane
regions in CEPI17 cells as shown by Z-sectioning analysis (14
sections at 2 μm/section from the top of the cell to the bottom)
performed using confocal microscopy (Figure 1B). Sections
at 2 μm, 3 μm, 7 μm, and 8 μm represent the membrane
associated  AQP5  and  sections  4  μm-7  μm  represent  the
cytosolic region of the cells. Primary corneal epithelial cells
(Figure 1C) were used as positive controls to show similar
localization of AQP5 in the CEPI17 cells. No fluorescence
was  detected  in  the  negative  controls  (data  not  shown).
Furthermore, as shown in Figure 1D, we also performed total
internal  reflection  (TIRF)  microscopy  followed  by
immunocytochemistry  to  study  the  cell  membrane
distribution  of  AQP5.  AQP5  is  abundantly  expressed  at
distinct spots on the cell membrane in comparison to the
epifluorescence image where the fluorescence appears to be
diffuse and cytosolic. The cells were also immunostained with
a cytosolic protein, tubulin followed by TIRF microscopy to
serve as a negative control (data not shown).
Effective down-regulation of AQP1 using siRNA in HCEC
cells: HCEC cells were transfected with AQP1 siRNA and
scrambled  control  siRNA  using  lipofectamine.  Significant
down-regulation  (98%)  in  the  AQP1  mRNA  level  was
observed in 48 h (lane 3, Figure 2A) following transfection
with AQP1 siRNA as determined by RT–PCR analysis. The
mRNA levels, however, increased at the 96 h time point and
hence all the downstream experiments were conducted 72 to
96 h after transfection. Significant down-regulation (97%) in
AQP1 protein synthesis was also observed 72 h (lane 5, Figure
2B)  after  transfection  with  AQP1  siRNA.  This  down-
regulation was determined by western blot analysis using
AQP1 antibody and the experiments were repeated three times
(n=3).
Effective down-regulation of AQP5 using siRNA in CEPI17
cells: CEPI17 cells were transfected with AQP5 siRNA and
scrambled  control  siRNA.  There  was  significant  down-
regulation  (96%)  in  the  AQP5  mRNA  levels  48  h  post
transfection  (lane  3,  Figure  2C)  in  cells  transfected  with
AQP5 siRNA as determined by RT–PCR analysis. Significant
Figure 2. Effective silencing of AQP1
and  AQP5  using  siRNA.  Down-
regulation  of  AQP1  expression  in
HCEC cells using siRNA as determined
by (A) RT–PCR and (B) western blot
analysis.  Down-regulation  of  AQP5
expression in CEPI17 cells using siRNA
as  determined  by  (C)  RT–PCR,  (D)
western  blot  analysis.  Panel  E  shows
down-regulation  of  AQP5  (green)  in
CEPI17  cells,  96  h  post  trasnfection
with  AQP5  siRNA.  AQP5  down
regulation  was  determined  by
Immunocytochemical  analysis  (DAPI
was used to stain the nucleus).
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1542down regulation (90%) in AQP5 protein synthesis was also
observed after 72 h (lane 4, Figure 2D) following transfection
with AQP5 siRNA as determined by western blot analysis
repeated  three  times.  This  result  was  also  confirmed  by
indirect  immunofluorescence  using  polyclonal  anti-AQP5
antibody 96 h following transfection with AQP5 siRNA. As
shown in Figure 2E, there is minimal expression of AQP5
(green) in the cells that were transfected with AQP5 siRNA,
whereas the expression of AQP5 is unaltered in the control
cells.
Effect of AQP1 down-regulation on HCEC migration and
proliferation: AQP1 siRNA was used to study the effect of
down regulation of AQP1 on migration of HCEC cells. HCEC
cell  line  was  transfected  with  AQP1  siRNA  and  wound-
healing assay was performed to study the effect of AQP1
siRNA on the migration of HCEC cells. As seen in Figure 3A,
AQP1 down regulation resulted in decrease in migration of
HCEC cells as determined by in vitro wound healing assay.
However, when the control siRNA was used to transfect the
HCEC cells it had no effect on cell migration (Figure 3A). The
area of the wound over time was measured using image J
software  as  described  earlier  and  statistical  analysis  was
performed. There was significant decrease in cell migration
30 h after the scratch was created (Figure 3B). The scratch
assay was also performed in the presence of 0.04% Mitomycin
C, an inhibitor of cell proliferation, and similar results were
obtained  (data  not  shown).  The  effect  of  AQP1  down
regulation on cell migration was also studied using the in vitro
matrigel cell migration assay (Figure 3C). As shown in Figure
3C, a significant decrease in cell migration was observed in
HCEC  cells  transfected  with  AQP1  siRNA.  HCEC  cells
transfected with scrambled siRNA were used as controls. To
study the effect of AQP1 down regulation on cell proliferation,
SRB assay was performed as described earlier. Significant
decrease in cell proliferation was also observed on AQP1
down-regulation as determined by SRB proliferation assay
(Figure  4A).  There  was  significant  decrease  in  cell
proliferation after 3 and 5 days following transfection with
AQP1  siRNA.  ERK  phosphorylation  was  monitored  as  a
marker for cell proliferation. There was also a significant
decrease in levels of phosphorylated ERK protein in AQP1
down-regulated cells when compared to the controls 96 h post
transfection (Figure 4B). There was no change in the levels of
phosphorylated ERK at other time points (data not shown).
This  was  determined  by  western  blot  analysis  using
phosphorylated  ERK  antibody.  Expression  levels  of  total
ERK was used as a loading control.
Effect  of  AQP5  down-regulation  on  CEPI17  migration,
proliferation and ERK phosphorylation: AQP5 siRNA was
used  to  study  the  effect  of  down  regulation  of  AQP5  on
migration of CEPI17 cells. CEPI17 cells were transfected with
AQP5 siRNA and wound-healing assay was performed to
study the effect of AQP5 siRNA on the migration of CEPI17
cells as described earlier. As seen in Figure 5A, AQP5 down
Figure  3.  Effect  of  siRNA  mediated
AQP1 down-regulation (AQP1DR) on
cell migration in HCEC cells. Panels A
and B show that AQP1DR decreased
cell  migration  as  determined  by  the
scratch wound healing assay in control
and AQP1DR cells. A decrease in cell
migration was significant at 24 h and 30
h p<0.05 and CI=95% as determined by
the paired T-Test (n=3). C: Decreased
cell migration was observed in HCEC
cells following AQP1DR as compared
to control cells, as determined by the in
vitro endothelial cell migration assay.
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1543regulation  resulted  in  significant  increase  in  migration  of
CEPI17 cells as determined by the in vitro wound-healing
assay. However, when control siRNA was used to transfect
the CEPI17 cells it had no effect on cell migration (Figure 5A).
The area of the wound over time was measured using image
J software and statistical analysis was performed. There was
significant increase in cell migration 18 h after the scratch was
created (Figure 5A,B). The scratch assay was also performed
in the presence of 0.04% Mitomycin C, an inhibitor of cell
proliferation,  and  similar  results  were  obtained  (data  not
shown). To study the effect of AQP5 down regulation on cell
proliferation, SRB assay was performed as described earlier.
Significant increase in cell proliferation was also observed on
AQP5 down-regulation as determined by SRB proliferation
assay (Figure 6A). This was significant after 3 and 5 days
following  transfection  with  AQP5  siRNA.  ERK
phosphorylation was monitored over time as a marker for cell
proliferation. There was, however, no significant change in
levels  of  phosphorylated  ERK  protein  in  AQP5  down-
regulated cells when compared to the controls at different time
points (96 h time point shown in Figure 6B, repeated three
times). This was determined by western blot analysis using
phosphorylated  ERK  antibody.  Expression  levels  of  total
ERK was used as a loading control.
DISCUSSION
We  used  HCEC  and  CEPI17  cell  lines  to  investigate  the
localization of AQP1 and AQP5. Primary corneal endothelial
and epithelial cells are extremely hard to culture and have a
very limited proliferative life span in vitro, which depends on
the age of the donor [28]. This was the main reason for opting
to use the CEPI17 cell line, which is a commonly used corneal
epithelial cell model [24]. Further, availability of tissue from
younger donors is very limited and hence the HCEC and
CEPI17 cell lines were used in our expression and down
regulation studies. Primary corneal epithelial cells had similar
AQP5 expression as the CEPI17 cells; this helped ascertain
that the CEPI17 was a suitable model for the described studies.
Primary endothelial cells are extremely hard to culture and
hence, they were not used in our experiments due to their lack
of  availability.  Our  studies  on  localization  of  AQPs  have
shown that both AQP1 and AQP5 are localized both to the
Figure  4.  Effect  of  siRNA  mediated
AQP1 down-regulation (AQP1DR) on
cell proliferation in HCEC cells. A: SRB
(Sulforhodamine B) assay was used to
determine  the  effect  AQP1  down
regulation  (AQP1DR)  on  HCEC
proliferation.  AQP1DR  decreased
HCEC cell proliferation (significant at 3
and  5  days  p<0.05,  95%  CI  as
determined by the paired T-Test, [n=3]).
B: Decrease in phosphorylated ERK 96
h post AQP1DR is shown by western
blot analysis in HCEC cells.
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1544cytosol and cell membrane. To localize the presence of AQP5
in  CEPI17  cells,  TIRF  microscopy  was  used.  TIRF
microscopy or evanescent wave microscopy is a specialized
type of confocal microscopy which allows the excitation of
fluorophores within a closely restricted zone (70 nm) of the
plasma membrane increasing the signal to noise ratio of the
plasma  membrane  to  cytosolic  fluorescence.  This  type  of
microscopy is commonly used to study plasma membrane
associated events [29]. Previously, localization of AQP1 and
AQP5 has been shown to be membrane associated in vivo
[30]. Our observation of localization of AQP1 and AQP5 in
both cytosol as well as membrane could be tissue/cell specific
or a purely in vitro phenomenon. Localization of the AQPs
has been shown to affect secretory function of tissues such as
salivary glands, lacrimal glands, and the pancreas in Sjorgen's
syndrome  [11].  Studies  have  shown  changes  in  protein
Figure  5.  Effect  of  siRNA  mediated
AQP5 down-regulation (AQP5DR) on
cell migration in CEPI17 cells. Panels
A and B show that AQP5DR decreased
cell  migration  as  determined  by  the
scratch wound healing assay in control
and AQP5DR cells. The decrease in cell
migration was significant at 24 h and 30
h p<0.05 and CI=95% as determined by
the paired T-Test, [n=3]).
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1545localization in normal versus diseased tissues from donors
with  Sjorgen's  syndrome  [31],  there  are  however  some
contradicting studies in this area [32]. Hence, localization of
these proteins may have considerable impact on function even
in ocular tissues.
Our  results  demonstrate  that  there  is  a  significant
decrease in cell migration and proliferation in HCEC cells
following AQP1 down regulation. Using siRNA we could
significantly down regulate the AQP1 mRNA and protein
levels. We have performed a detailed time course study to
determine the time point where there is maximum down-
regulation  at  the  protein  level  for  our  downstream
experiments.  There  is  however  a  reoccurrence  of  AQP1
mRNA at 96 h following lipofectamine mediated transfection
with AQP1 siRNA. This could be due to two possible reasons:
(1) The silencing was only transient and after 96 h the siRNA
mediated silencing was abrogated beyond that time point, (2)
AQP1 is an osmoinducible water channel and the AQP1 gene
has a hyper tonicity-responsive element [33]. It is therefore
possible that there is a resurgence of AQP1 at 96 h in response
to  changes  in  cellular  tonicity,  but  this  needs  further
investigation.  However,  since  the  experiments  we  have
described  are  performed  at  the  time  point  when  there  is
significant down regulation of AQP1, the reoccurrence of the
mRNA after 96 h following transfection will not affect our
data.
Down regulation of AQP1 has been shown to be involved
in decreased cell migration in several cell types including
human melanoma cell lines, human microvascular endothelial
cells,  kidney  epithelial  cells,  and  gastric  epithelial  cells.
Overexpression of AQP1 has been reported in proliferating
tumor  vessels  suggesting  its  involvement  in  tumor
angiogenesis  [34].  However,  corneal  endothelial  cells  are
different from vascular endothelial cells as they are derived
from the neural crest and are in fact leaky epithelial cells. Also,
the  proliferative  capacity  of  normal  human  corneal
endothelial  cells  depends  on  the  age  of  the  donor  and  it
decreases  with  the  age  of  the  donor  [28].  Also,  corneal
endothelial cells, as compared to vascular endothelial cells,
have a different function, which is to act as a water pump, and
Figure  6.  Effect  of  siRNA  mediated
AQP5 down-regulation (AQP5DR) on
cell  proliferation  in  CEPI17  cells.  A:
SRB  assay  shows  that  AQP5DR
increased cell proliferation in CEPI17
cells (significant at 3 and 5 days p<0.05,
95% CI as determined by the paired T-
Test, [n=3]). There was no significant
difference in phosphorylated ERK 96 h
post transfection in CEPI17 cells when
compared to the controls as shown by
western blot analysis (B).
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1546therefore these cells do not form blood vessels. The results
however show a similar response to AQP1 down-regulation
as the vascular endothelial cells that have been previously
reported [22].
Our  data  also  show  a  significant  increase  in  cell
proliferation and migration upon AQP5 down-regulation in a
corneal epithelial cell line (CEPI17). Previous studies have
shown  an  upregulation  of  AQP5  in  ovarian  tumors  [35],
colorectal carcinomas [10], and in human small cell lung
cancer [36]. These studies have also shown the involvement
of the ERK signaling cascades in response to changes in
AQP5 expression levels [37]. However, we did not observe
significant increase in phosphorylated ERK, which implies
the involvement of an alternate proliferation pathway that
needs to be explored. This could be a tissue specific event
considering the fact that the cornea is an immune privileged
site and corneal cancers are rare. It has been reported that
AQP3 plays a major role in corneal re-epithelialization and
AQP3-deficient mice have defects in corneal epithelial cell
migration and proliferation [38]. It is not known and further
studies are required to determine whether down-regulation of
AQP5 could cause an increased expression of AQP3, which
could lead to increased cell proliferation and migration.
In both cell types (CEPI17 and HCEC) we did not observe
any  significant  changes  in  cell  size  and  cell  morphology
following AQP down regulation as reported previously in
primary cultures of astrocytes, where there was significant
decrease in cell size following AQP4 down regulation [39,
40]. However, this phenomenon was observed only in vitro
culture following transfection with AQP4 siRNA, however,
the astrocytes from AQP4 knock out models were similar in
size and morphology to normal controls [39,41].
The numerous functions of AQPs in tissue homeostasis
and disease are currently being explored for clinical benefits.
Currently, AQP targeting drugs are also being considered to
be  of  potential  benefit  as  diuretics  and  in  treatment  of
conditions such as epilepsy, brain edema, glaucoma, wound
healing, obesity and cancer. Our data provides evidence that
AQP1 and AQP5 could play an important role in corneal
wound healing. Down regulation of AQP1 in HCEC decreases
ERK  dependent  proliferation  and  migration  suggesting
AQP1  stimulators  may  have  significant  implications  in
corneal  wound  healing  and  neovascularization.  However,
down  regulation  of  AQP5  increases  the  proliferation  and
migration of CEPI17 cells suggesting AQP5 inhibitors may
have significant implications in corneal wound healing.
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